North America Alpha-Glucosidase Inhibitors Market - Growth, Trends, Covid-19 Impact, and Forecasts (2022 - 2027)

North America Alpha-Glucosidase Inhibitors Market - Growth, Trends, Covid-19 Impact, and Forecasts (2022 - 2027)

The North America Alpha-Glucosidase Inhibitors Market is expected to register a CAGR greater than 2.5% over the forecast period.

In North America, the United States is having the highest number of COVID cases with 82 million by April 2022, the country also registered the highest death rate. According to the Diabetes Voice article published in May 2020, close to 40,000 deaths are people with diabetes. In the North American region diabetes patients are more concerned about stocking up the monitoring and managing devices due to this the market increased during these years.

The North American region had witnessed an astounding increase in the prevalence of diabetes, in recent years. In developed countries, such as the United States and Canada, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. Diabetes is associated with many health complications. Comparing the population with and without diabetes, those with diabetes have a 300% increased risk of being hospitalized and thus incur more healthcare expenses compared to non-diabetic people.​ Patients with Type 2 diabetes require many corrections throughout the day for maintaining nominal blood glucose levels, such as the administration of additional insulin or ingestion of additional carbohydrates.

The World Health Assembly agreed on a Resolution to strengthen diabetes prevention and control in May 2021. It recommends actions such as increasing access to diabetes medicines and health products and assessing the feasibility and potential value of establishing a web-based tool to share information relevant to market transparency for diabetes medicines and health products.

The FDA approves AGIs for the treatment of type 2 diabetes mellitus. They have shown some benefits in type 1 diabetes mellitus and gestational diabetes mellitus but are not FDA-approved for these indications. Acarbose has been shown to decrease body weight in a worldwide observational study. AGIs are particularly useful for reducing postprandial hyperglycemia. They modestly decrease glycosylated hemoglobin levels and also reduce postprandial insulin concentration. Compared with oral antihyperglycemic drugs, they also reduce glucose variability throughout the day. They, however, do not affect fasting insulin and serum triglyceride concentrations.

This is driving the demand for Alpha-Glucosidase Inhibitors in North America, thereby driving the market in focus during the forecast period.​

Key Market TrendsRising Diabetes Prevalence in North America Region

According to the National Diabetes Statistics Report 2021, approximately 37.3 million people, or approximately 11.3% of the US population, have diabetes. People who are overweight are more likely to develop prediabetes, which can progress to Type 2 diabetes, putting them at risk for complications, acute and long-term complications, and death. Obesity, an unhealthy diet, and a sedentary lifestyle are all contributing to an increase in newly diagnosed Type 1 and Type 2 diabetes cases. The increased prevalence of diabetic patients and global healthcare expenditure are indicators of a greater proclivity for diabetic drugs. Type 2 diabetes (T2D) is becoming more common and is linked to an increased risk of cardiovascular and renal disease. Meglitinides are oral medications used to treat Type 2 diabetes in conjunction with lifestyle changes. They work by stimulating insulin release from pancreatic beta cells, which lowers blood glucose levels.

The United States is Expected to Dominate North America Alpha-Glucosidase Inhibitors Market.

Alpha-glucosidase inhibitors are oral anti-diabetic drugs used for diabetes mellitus type 2 that work by preventing the digestion of carbohydrates. Carbohydrates are converted into monosaccharides by alpha-glucosidase enzymes present in cells lining the intestine, enabling monosaccharides to be absorbed through the intestine. Hence, alpha-glucosidase inhibitors reduce the impact of dietary carbohydrates on blood sugar. Alpha-glucosidase inhibitors are used to establish greater glycemic control over hyperglycemia in diabetes mellitus type 2, they may be used as monotherapy in conjunction with an appropriate diabetic diet and exercise, or they may be used in conjunction with other anti-diabetic drugs. Therefore, they have been potential candidates for treating patients affected by COVID-19 infection, with or even without type 2 diabetes, as well as excellent antidiabetic (glucose-lowering) agents during COVID-19 pandemic times.

Owing to the aforementioned factors the market is expected to grow during the forecast period.

Competitive Landscape

The market studied is highly fragmented into many manufacturers like Bayer, SunPharma, Pfizer, and Takeda, holding a presence in all regions.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.